TY - JOUR
T1 - Sirolimus vs. paclitaxel-eluting stent to coronary intervention in dialysis patients
AU - Kamoi, Daisuke
AU - Ishii, Hideki
AU - Takahashi, Hiroshi
AU - Aoyama, Toru
AU - Toriyama, Takanobu
AU - Tanaka, Miho
AU - Kawamura, Yoshihiro
AU - Kawashima, Kazuhiro
AU - Yoshikawa, Daiji
AU - Amano, Tetsuya
AU - Uetani, Tadayuki
AU - Matsubara, Tatsuaki
AU - Murohara, Toyoaki
N1 - Funding Information:
This study was supported by a grant from the Aichi Kidney Foundation, Nagoya, Japan .
PY - 2013
Y1 - 2013
N2 - Background: Patients on maintenance hemodialysis (HD) are at high risk for restenosis after percutaneous coronary intervention (PCI) even if treated with a sirolimus-eluting stent (SES). The aim of this study was to compare the effects of SES and paclitaxel-eluting stent (PES) in preventing restenosis in HD patients with coronary artery disease. Methods: A total of 100 consecutive patients on HD who underwent PCI were enrolled into the study. They were randomly assigned to receive either SES or PES. We compared follow-up angiographic outcomes between the SES and PES groups at 8-month follow-up. Results: The angiographical restenosis rate, defined as % diameter stenosis > 50% at 8-month follow-up, was 19.7% in the SES group and 20.0% in the PES group (p = 0.97). Late loss was also similar between the two groups (0.49 ± 0.70 mm vs. 0.48 ± 0.91 mm, P = 0.94). There were no significant differences in the rates of all-cause death, non-fatal myocardial infarction, or TLR due to stent restenosis-induced ischemia between the two groups (2.0% vs. 4.0%, p = 0.56, 2.0% vs. 4.0%, p = 0.56, and 16.0% vs. 12.0%, p = 0.57, respectively). Conclusions: There was no significant difference in angiographical outcome at 8-month follow-up between HD patients treated with SES and PES. Even if treated with DES including SES and PES, patients on HD are at high risk of restenosis after PCI.
AB - Background: Patients on maintenance hemodialysis (HD) are at high risk for restenosis after percutaneous coronary intervention (PCI) even if treated with a sirolimus-eluting stent (SES). The aim of this study was to compare the effects of SES and paclitaxel-eluting stent (PES) in preventing restenosis in HD patients with coronary artery disease. Methods: A total of 100 consecutive patients on HD who underwent PCI were enrolled into the study. They were randomly assigned to receive either SES or PES. We compared follow-up angiographic outcomes between the SES and PES groups at 8-month follow-up. Results: The angiographical restenosis rate, defined as % diameter stenosis > 50% at 8-month follow-up, was 19.7% in the SES group and 20.0% in the PES group (p = 0.97). Late loss was also similar between the two groups (0.49 ± 0.70 mm vs. 0.48 ± 0.91 mm, P = 0.94). There were no significant differences in the rates of all-cause death, non-fatal myocardial infarction, or TLR due to stent restenosis-induced ischemia between the two groups (2.0% vs. 4.0%, p = 0.56, 2.0% vs. 4.0%, p = 0.56, and 16.0% vs. 12.0%, p = 0.57, respectively). Conclusions: There was no significant difference in angiographical outcome at 8-month follow-up between HD patients treated with SES and PES. Even if treated with DES including SES and PES, patients on HD are at high risk of restenosis after PCI.
UR - http://www.scopus.com/inward/record.url?scp=84877047472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877047472&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2011.09.078
DO - 10.1016/j.ijcard.2011.09.078
M3 - Article
C2 - 22000423
AN - SCOPUS:84877047472
SN - 0167-5273
VL - 165
SP - 533
EP - 536
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 3
ER -